| Ranbaxy recalls drug in US | 20-NOV-09 |
|
| India’s leading drug maker Ranbaxy has initiated a voluntary recall of 4,348 cartons of its skin infection drug Sotret (isotretinoin) in the United States. The entire lot pertains to a single batch of tablets which were found to be ‘out of specification’. |
|
|
|
| Ranbaxy finding ways to make two of four acquisitions work | 16-NOV-09 |
|
| The key strategic investments made by the erstwhile promoters of Ranbaxy Laboratories may seem to be floundering on the surface, but the Daiichi-owned company is looking at bigger engagements with at least two of these companies. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| New tonic for Revital | 02-NOV-09 |
|
| Yuvraj Singh has just told us the secret of his power-packed performances. It’s Revital, a combination of vitamin, mineral and the Chinese wonder herb Ginseng. |
|
|
|
| Ranbaxy Labs reports net profit of Rs 116 cr | 27-OCT-09 |
|
| India’s biggest drug maker, Ranbaxy Laboratories, has posted a net profit of Rs 116.6 crore for its third quarter ended September, against a net loss of Rs 394.5 crore in the same period last year, which had been largely attributed to mark-to-market exchange losses. |
|
|
|
| Ranbaxy wins US court ruling on Roche patent | 17-OCT-09 |
|
| Daiichi Sankyo-owned Ranbaxy Laboratories has won a decisive ruling from the District Court of New Jersey that its generic version of valganciclovir, prescribed for HIV/Aids patients and for organ transplantation-related infections, does not infringe the patent rights of Swiss drug maker Roche's anti-infection drug, Valcyte. |
|
|
|
|
|
|
|
|
|
| Experts meet to review H1N1 Swine Flu Pandemic affecting the world and India | 21-SEP-09 |
|
| Ranbaxy Science Foundation (RSF), a non-profit organization set-up by Ranbaxy Laboratories Limited (RLL), organized its XXIII Round Table Conference on the “Pandemic Influenza Update” on September 19, 2009 in New Delhi. The programme was moderated by Shobha Broor, All India Institute of Medical Sciences, New Delhi and Prof. T. Jacob John, Formerly Professor and Head, Departments of Clinical Microbiology and Virology, Christian Medical College, Vellore. Jai P. Narain Director, Dept. |
|
|
|
| Ranbaxy to market S Korean product | 18-SEP-09 |
|
| Ranbaxy Laboratories Ltd has entered into an in-licencing agreement with South Korean biotech firm Medy-Tox Inc for supply of its dermatology product Neuronox in the Indian market. |
|
|
|
| Ranbaxy strengthens presence in Dermatological segment | 17-SEP-09 |
|
| Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Company has entered into a strategic in-licensing agreement for the Indian market, with Medy-Tox Inc. (Medy-Tox), South Korea’s largest Botulinum –Toxin specialized Biotech Venture, for its cosmetic product, Neuronox. The introduction of this new alternative brand of Purified Botulinum Toxin Type –A, will strengthen the Company’s presence in the Dermatological segment. |
|
|
|
|
|
|
Content Guide
